Current market catalysts

StoneX Group Announces Buyback Program Of Up To 5M Shares For FY2027, Running October 1, 2026 Through September 30, 2027

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000913760/000091376026000041/intl-20260826.htm

Goldman Sachs Maintains Neutral on Victory Capital Holdings, Raises Price Target to $117

Goldman Sachs analyst Alexander Blostein maintains Victory Capital Holdings (NASDAQ:VCTR) with a Neutral and raises the price target from $100 to $117.

HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.

8-K filing — MALIBU BOATS, INC. (MBUU)

Filed: 2026-08-28 AccNo: 0001590976-26-000040 Size: 364 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

BTIG Reiterates Buy on InvenTrust Properties, Maintains $37 Price Target

BTIG analyst Michael Gorman reiterates InvenTrust Properties (NYSE:IVT) with a Buy and maintains $37 price target.

B of A Securities Maintains Buy on Affirm Holdings, Raises Price Target to $104

B of A Securities analyst Matthew O'Neill maintains Affirm Holdings (NASDAQ:AFRM) with a Buy and raises the price target from $93 to $104.

8-K filing — StoneX Group Inc. (SNEX)

Filed: 2026-08-28 AccNo: 0000913760-26-000041 Size: 146 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

B of A Securities Maintains Neutral on Gap, Raises Price Target to $27

B of A Securities analyst Lorraine Hutchinson maintains Gap (NYSE:GAP) with a Neutral and raises the price target from $26 to $27.

Hecate Energy And EGH Acquisition Say $1.2B Business Combination Now Expected To Close In Early Q1 2027; Lender Legal And Documentation Matters, Related Litigation Fully Resolved

Needham Maintains Buy on Affirm Holdings, Raises Price Target to $100

Needham analyst Kyle Peterson maintains Affirm Holdings (NASDAQ:AFRM) with a Buy and raises the price target from $90 to $100.

B of A Securities Maintains Buy on Ulta Beauty, Lowers Price Target to $650

B of A Securities analyst Lorraine Hutchinson maintains Ulta Beauty (NASDAQ:ULTA) with a Buy and lowers the price target from $685 to $650.

Earlier: China Issued Guidelines Requiring Local Governments To Shift Toward Sales Of Completed Housing Units To Curb Delivery Risks, Stabilize Property Sector

S&P 500 Outlook: September is the 'Worst Month of the Year' but Ryan Detrick Says 2026 Could Defy the Odds

September is historically the worst month for the S&P 500, but Ryan Detrick explains why a green August means 2026 could defy the odds.

8-K filing — Pluri Inc. (PLUR)

Filed: 2026-08-28 AccNo: 0001213900-26-094638 Size: 809 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Kazia Therapeutics Prices ~$40M Offering Of 2.58M American Depositary Shares At $17.825 Per ADS

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

B of A Securities Maintains Neutral on Elastic, Raises Price Target to $108

B of A Securities analyst Koji Ikeda maintains Elastic (NYSE:ESTC) with a Neutral and raises the price target from $90 to $108.

Mobia Medical Says Paired Vagus Nerve Stimulation Included In 2026 AHA/ASA Adult Stroke Rehabilitation Guideline As Option To Improve Upper-Limb Function In Chronic Stroke Survivors

8-K filing — MID AMERICA APARTMENT COMMUNITIES INC. (MAA-PI)

Filed: 2026-08-28 AccNo: 0001193125-26-372238 Size: 254 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

United Therapeutics To Present Eight Clinical Studies In PAH And Fibrotic Lung Diseases At ESC 2026 In Munich And ERS 2026 In Barcelona

ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening in PAH patients

Market-Moving News for August 28th

AFRM: 13% | Affirm Holdings shares are trading higher after the company reported strong Q4 financial results. GAP: 16% | Gap shares are trading higher after the company reported better-than-expected Q2 adjusted EPS

FiscalNote Holdings Lowers FY2026 Sales Guidance from $75.000M-$78.000M to $74.000M-$76.000M vs $80.830M Est

FiscalNote Holdings (OTC:NOTE) lowers FY2026 sales outlook from $75.000 million-$78.000 million to $74.000 million-$76.000 million vs $80.830 million estimate.

XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency

XORTX Therapeutics Inc. ("XORTX" or the "Company") NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and

Top 3 Consumer Stocks That May Rocket Higher This Quarter

Oversold stocks in consumer discretionary sector present buying opportunity. RSI compares stock strength on up/down days, helps predict short term performance. RSI below 30 indicates oversold.

Needham Maintains Buy on RingCentral, Raises Price Target to $85

Needham analyst Joshua Reilly maintains RingCentral (NYSE:RNG) with a Buy and raises the price target from $55 to $85.

Billionaire Ken Griffin Is Shifting His AI Bets. Here's What He's Buying and Selling.

Ken Griffin's Citadel hedge fund is shifting its AI investment strategy by selling positions in Nvidia, Broadcom, and Micron Technology while increasing exposure to Amazon and Microsoft. The moves reflect a market preference for companies demonstrating tangible results from their massive AI infrastructure spending, with Amazon's AWS achieving fastest growth in four years and Microsoft maintaining strong free cash flow despite $175 billion in projected annual AI spending.

Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.

Investor Notice: Rackspace Technology (NASDAQ:RXT) Accused of Misleading Investors in Securities Fraud Class Action – Contact BFA Law if You Lost Money

A securities fraud class action lawsuit has been filed against Rackspace Technology (NASDAQ:RXT) for allegedly misleading investors about its AI efforts and their financial impact. The company's stock plummeted 33.6% on July 9, 2026, after revealing that AI investments would require significant resource reallocation away from revenue-generating segments, leading to a $150 million cut in full-year revenue guidance. Investors have until September 28, 2026 to request lead plaintiff status.

Chagee Announces Second Quarter 2026 Unaudited Financial Results

Chagee Holdings Limited (NASDAQ: CHA) reported Q2 2026 results with net revenues increasing 2.5% to RMB3,414.6 million and GAAP net income rising significantly to RMB464.8 million from RMB77.2 million year-over-year. However, the company faced headwinds with Greater China GMV declining and same-store GMV growth remaining negative at -16.1%. The company expanded its teahouse network to 7,639 locations and authorized a US$150 million share repurchase program.

The S&P 500 Is Repeating an Ominous Pattern Not Seen in 26 Years. History Says This Is What Usually Happens Next, and Why This Time Could Be Different.

The S&P 500 is trading near record highs with a CAPE ratio at its highest level since the dot-com bubble, historically associated with market corrections. However, unlike the 1990s, today's AI-driven tech companies have substantial earnings, cash flow, and competitive advantages rather than speculative valuations. Investors should consider trimming gains while maintaining core holdings in quality companies with durable competitive moats.

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, a clinical-stage biotechnology company, announced fiscal year 2026 results marking its transition to clinical development with initiation of Phase 1 trials for IBIO-600, a long-acting anti-myostatin antibody. The company advanced IBIO-610 into IND-enabling studies showing fat-selective weight loss potential and completed successful financings totaling $126 million, extending cash runway into fiscal 2028. R&D expenses increased to $19.6 million from $8.3 million year-over-year, while the company held $88 million in cash and investments.